Suranganie Dharmawardhane
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| rac GTP-Binding Proteins | 8 | 2022 | 21 | 4.000 |
Why?
|
| cdc42 GTP-Binding Protein | 6 | 2021 | 23 | 3.100 |
Why?
|
| Breast Neoplasms | 16 | 2021 | 1426 | 2.830 |
Why?
|
| rac1 GTP-Binding Protein | 5 | 2021 | 44 | 2.170 |
Why?
|
| Stilbenes | 7 | 2016 | 41 | 2.100 |
Why?
|
| Antineoplastic Agents | 9 | 2019 | 756 | 2.030 |
Why?
|
| Carbazoles | 7 | 2021 | 43 | 2.010 |
Why?
|
| Pyrimidines | 7 | 2021 | 112 | 1.860 |
Why?
|
| Vitis | 4 | 2016 | 29 | 1.330 |
Why?
|
| Cell Line, Tumor | 20 | 2021 | 2128 | 1.190 |
Why?
|
| Isoflavones | 4 | 2021 | 125 | 1.120 |
Why?
|
| Neoplasm Metastasis | 7 | 2017 | 211 | 1.080 |
Why?
|
| Eukaryotic Initiation Factor-4G | 3 | 2015 | 11 | 1.070 |
Why?
|
| Catechin | 3 | 2016 | 30 | 1.020 |
Why?
|
| Quercetin | 3 | 2016 | 41 | 0.990 |
Why?
|
| Genistein | 2 | 2016 | 41 | 0.920 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 781 | 0.910 |
Why?
|
| GTP-Binding Proteins | 1 | 2022 | 57 | 0.880 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 396 | 0.770 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 117 | 0.770 |
Why?
|
| Cell Proliferation | 12 | 2021 | 1149 | 0.760 |
Why?
|
| Cell Movement | 7 | 2022 | 545 | 0.740 |
Why?
|
| Mice | 15 | 2022 | 5668 | 0.720 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2015 | 52 | 0.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 178 | 0.710 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 209 | 0.700 |
Why?
|
| Saccharomycetales | 1 | 2018 | 7 | 0.670 |
Why?
|
| Cell Polarity | 1 | 2018 | 53 | 0.650 |
Why?
|
| Mice, Nude | 7 | 2016 | 323 | 0.630 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2016 | 245 | 0.620 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2009 | 70 | 0.610 |
Why?
|
| Female | 24 | 2021 | 19873 | 0.610 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2015 | 173 | 0.580 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2016 | 107 | 0.570 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 122 | 0.570 |
Why?
|
| Animals | 19 | 2022 | 14307 | 0.560 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2015 | 406 | 0.550 |
Why?
|
| Protein Biosynthesis | 2 | 2015 | 123 | 0.550 |
Why?
|
| Cell Survival | 7 | 2017 | 818 | 0.540 |
Why?
|
| Receptors, Estrogen | 2 | 2015 | 145 | 0.540 |
Why?
|
| Signal Transduction | 4 | 2018 | 1802 | 0.540 |
Why?
|
| Actins | 2 | 2007 | 142 | 0.530 |
Why?
|
| Drug Design | 2 | 2013 | 154 | 0.530 |
Why?
|
| Breast | 1 | 2016 | 134 | 0.520 |
Why?
|
| Mice, SCID | 4 | 2021 | 143 | 0.520 |
Why?
|
| Estradiol | 2 | 2007 | 244 | 0.490 |
Why?
|
| Humans | 29 | 2021 | 34853 | 0.470 |
Why?
|
| Phytoestrogens | 1 | 2012 | 35 | 0.440 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 59 | 0.430 |
Why?
|
| Quinazolines | 1 | 2012 | 31 | 0.420 |
Why?
|
| Reishi | 1 | 2011 | 6 | 0.410 |
Why?
|
| Up-Regulation | 3 | 2021 | 490 | 0.400 |
Why?
|
| MicroRNAs | 1 | 2016 | 386 | 0.390 |
Why?
|
| Plant Extracts | 1 | 2013 | 250 | 0.370 |
Why?
|
| Neoplasms | 2 | 2018 | 1033 | 0.370 |
Why?
|
| Cytoskeleton | 2 | 2007 | 98 | 0.350 |
Why?
|
| p21-Activated Kinases | 3 | 2013 | 16 | 0.350 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2009 | 21 | 0.350 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 42 | 0.340 |
Why?
|
| Fluorescent Dyes | 2 | 2006 | 173 | 0.330 |
Why?
|
| Aminoquinolines | 3 | 2013 | 14 | 0.330 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2007 | 16 | 0.300 |
Why?
|
| Luminescent Agents | 1 | 2006 | 3 | 0.300 |
Why?
|
| Apoptosis | 4 | 2021 | 1317 | 0.290 |
Why?
|
| Luminescent Proteins | 1 | 2006 | 74 | 0.290 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2006 | 196 | 0.270 |
Why?
|
| Estrogens | 1 | 2007 | 190 | 0.270 |
Why?
|
| Focal Adhesions | 1 | 2005 | 15 | 0.260 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 239 | 0.250 |
Why?
|
| Down-Regulation | 2 | 2016 | 420 | 0.230 |
Why?
|
| Molecular Structure | 4 | 2019 | 467 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 984 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 3 | 2011 | 247 | 0.230 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2022 | 28 | 0.230 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2021 | 107 | 0.220 |
Why?
|
| Cell Division | 1 | 2022 | 296 | 0.210 |
Why?
|
| Cell Cycle | 2 | 2016 | 309 | 0.210 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 1300 | 0.210 |
Why?
|
| Neoplasm Transplantation | 2 | 2012 | 114 | 0.200 |
Why?
|
| Spheroids, Cellular | 1 | 2021 | 28 | 0.200 |
Why?
|
| Point Mutation | 1 | 2021 | 88 | 0.200 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2019 | 36 | 0.200 |
Why?
|
| Blotting, Western | 3 | 2014 | 834 | 0.190 |
Why?
|
| Receptor, erbB-2 | 1 | 2021 | 122 | 0.190 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2019 | 14 | 0.180 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 162 | 0.180 |
Why?
|
| Disease Progression | 3 | 2019 | 580 | 0.180 |
Why?
|
| Estrogen Receptor beta | 2 | 2013 | 37 | 0.180 |
Why?
|
| Adipocytes | 1 | 2019 | 54 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 4 | 2014 | 480 | 0.170 |
Why?
|
| Cell Communication | 1 | 2019 | 93 | 0.170 |
Why?
|
| Estrogen Receptor alpha | 2 | 2013 | 105 | 0.170 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2012 | 286 | 0.170 |
Why?
|
| Indoles | 1 | 2019 | 154 | 0.160 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2011 | 185 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2014 | 242 | 0.160 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 555 | 0.140 |
Why?
|
| Dietary Supplements | 2 | 2021 | 196 | 0.140 |
Why?
|
| Pseudopodia | 2 | 2007 | 15 | 0.140 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 49 | 0.140 |
Why?
|
| Epidermal Growth Factor | 2 | 2007 | 63 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2016 | 53 | 0.140 |
Why?
|
| Protein Binding | 1 | 2018 | 913 | 0.130 |
Why?
|
| bcl-Associated Death Protein | 1 | 2014 | 6 | 0.130 |
Why?
|
| Pregnenolone | 1 | 2014 | 10 | 0.120 |
Why?
|
| Linear Models | 1 | 2015 | 253 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 12 | 0.120 |
Why?
|
| Hela Cells | 1 | 2015 | 344 | 0.120 |
Why?
|
| Organometallic Compounds | 1 | 2014 | 68 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2013 | 29 | 0.120 |
Why?
|
| Mice, Hairless | 1 | 2013 | 8 | 0.120 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2012 | 14 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 605 | 0.110 |
Why?
|
| RNA, Neoplasm | 1 | 2012 | 25 | 0.110 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 87 | 0.110 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 22 | 0.110 |
Why?
|
| Adenylate Kinase | 1 | 2012 | 13 | 0.110 |
Why?
|
| Catenins | 1 | 2011 | 3 | 0.100 |
Why?
|
| bcl-X Protein | 1 | 2011 | 23 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 41 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2014 | 1152 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 901 | 0.100 |
Why?
|
| Sirolimus | 1 | 2012 | 58 | 0.100 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 72 | 0.100 |
Why?
|
| Cadherins | 1 | 2011 | 82 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2012 | 194 | 0.100 |
Why?
|
| Binding Sites | 1 | 2012 | 597 | 0.090 |
Why?
|
| Postmenopause | 2 | 2021 | 125 | 0.090 |
Why?
|
| Enzyme Activation | 2 | 2013 | 423 | 0.090 |
Why?
|
| Obesity | 1 | 2017 | 965 | 0.090 |
Why?
|
| Asteraceae | 1 | 2007 | 3 | 0.080 |
Why?
|
| Saponins | 1 | 2007 | 5 | 0.080 |
Why?
|
| Triterpenes | 1 | 2007 | 12 | 0.080 |
Why?
|
| Genes, Dominant | 1 | 2007 | 18 | 0.080 |
Why?
|
| Optical Fibers | 1 | 2006 | 6 | 0.080 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2007 | 14 | 0.080 |
Why?
|
| Fiber Optic Technology | 1 | 2006 | 10 | 0.070 |
Why?
|
| Optics and Photonics | 1 | 2007 | 25 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 968 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 53 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2009 | 306 | 0.070 |
Why?
|
| Transfection | 1 | 2007 | 496 | 0.070 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2005 | 17 | 0.070 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2005 | 18 | 0.070 |
Why?
|
| Microscopy, Confocal | 2 | 2004 | 210 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2005 | 56 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 121 | 0.060 |
Why?
|
| Inflammation | 2 | 2019 | 577 | 0.060 |
Why?
|
| Phenotype | 1 | 2005 | 650 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2005 | 360 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 600 | 0.050 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2002 | 30 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2002 | 89 | 0.050 |
Why?
|
| 3T3-L1 Cells | 1 | 2019 | 14 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2019 | 44 | 0.050 |
Why?
|
| Culture Media | 1 | 2019 | 84 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2014 | 392 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 376 | 0.040 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2017 | 11 | 0.040 |
Why?
|
| STAT Transcription Factors | 1 | 2014 | 10 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 52 | 0.030 |
Why?
|
| Calibration | 1 | 2014 | 55 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 105 | 0.030 |
Why?
|
| beta Catenin | 1 | 2014 | 46 | 0.030 |
Why?
|
| Mastocytosis | 1 | 2013 | 2 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2014 | 79 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2013 | 6 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 171 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2013 | 83 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2561 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2013 | 80 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 445 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2014 | 878 | 0.030 |
Why?
|
| Kidney | 1 | 2014 | 322 | 0.030 |
Why?
|
| Liver | 1 | 2014 | 447 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 1530 | 0.020 |
Why?
|
| Middle Aged | 1 | 2021 | 9642 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 129 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 281 | 0.020 |
Why?
|
| Contrast Media | 1 | 2007 | 95 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 11034 | 0.020 |
Why?
|
| Streptavidin | 1 | 2004 | 6 | 0.020 |
Why?
|
| Fluorometry | 1 | 2004 | 15 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 33 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2004 | 100 | 0.010 |
Why?
|
| Biopsy | 1 | 2004 | 151 | 0.010 |
Why?
|
| Mouth Neoplasms | 1 | 2004 | 70 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2004 | 81 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 649 | 0.010 |
Why?
|